Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company (NYSE: LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley ...

Eli Lilly and Company (NYSE:LLY) is among the 12 Best Ethical Companies to Invest in 2025. Eli Lilly and Company (NYSE:LLY) ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly and Company will spend $3 billion to bolster its injectable product manufacturing in Pleasant Prairie. Eli Lilly buys another Kenosha County building, for $40 million.

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Then, by applying the company's long-term price-to-sales (P/S) ratio of 17.6 to this revenue projection, Eli Lilly would reach a market cap slightly above $1 trillion by 2030.